Merck Gets European Commission's Approval for Keytruda in Esophageal-Cancer Patients
June 29 2021 - 7:28AM
Dow Jones News
By Dave Sebastian
Merck & Co. Inc. said the European Commission has approved
its Keytruda drug in combination with chemotherapy for the
treatment of certain patients with esophageal cancer.
The approval lets the company market the Keytruda combination in
all 27 European Union member states, as well as Iceland,
Lichtenstein, Norway and Northern Ireland, Merck said Tuesday.
Merck said the approval is based on a Phase 3 trial in which a
Keytruda combination demonstrated improvements in overall survival
and progression-free survival.
The company said it is continuing to study Keytruda in multiple
settings and stages of gastrointestinal cancer, including studies
in esophageal, gastric, hepatobiliary, pancreatic, colorectal and
anal cancers.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
June 29, 2021 07:14 ET (11:14 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024
